转移性APMS前列腺癌对ARPI超常应答与耐药的临床及基因组决定因素
该回顾性研究纳入2015-2024年接受ADT/ARPI治疗的APMS前列腺癌患者,以PFS上四分位(>53.36个月)和下四分位(<10.41个月)定义超常应答(ER)和耐药/无应答(NR)。结果显示抑癌基因改变与NR相关,TP53、MYC、BRCA2和RAD21改变与更差PFS或OS相关,而ECOG<1、无痛、低瘤负荷、较高血红蛋白和白蛋白及正常碱性磷酸酶与更好结局相关。
要点
- 抑癌基因改变(伴或不伴增殖基因共改变)与NR相关,但无单一改变预测ER。
- TP53、MYC、BRCA2和RAD21改变与更差PFS或OS相关,MYC获得在多变量分析中与OS独立相关。
- ECOG<1、无痛、低瘤负荷、较高血红蛋白和白蛋白及正常碱性磷酸酶与更好PFS、OS和PSA反应相关。
核心结论
- 在真实世界APMS队列中识别出ADT/ARPI治疗前临床和基因组预测因素,与患者获益和长期生存相关。
研究设计与样本
- 回顾性综述2015-2024年接受ADT/ARPI的APMS患者,共3363例处方ADT/ARPI,224例治疗APMS,154例(69%)接受时间性分子检测。
主要发现
- ≥1个抑癌基因改变伴或不伴增殖基因共改变与NR相关,无单一改变预测ER。
- ECOG<1、无痛、低瘤负荷、较高血红蛋白和白蛋白及正常碱性磷酸酶与改善PFS、OS和12个月PSA nadir<0.2 ng/mL相关。
- TP53改变与PFS(HR 1.60 [95%CI 1.02-2.50],p=0.039)和OS(HR 1.91 [95%CI 1.05-3.49],p=0.035)较差相关。
- MYC改变与PFS(HR 2.01 [95%CI 1.03-3.91],p=0.040)和OS(HR 3.81 [95%CI 1.81-7.99],p<0.001)较差相关;BRCA2与PFS(HR 2.12 [95%CI 1.02-4.42],p=0.045)相关;RAD21与OS(HR 2.55 [95%CI 1.13-5.77],p=0.024)相关。
- 多变量分析中MYC获得与OS相关(HR 4.41 [95%CI 1.24-15.7],p=0.022);增殖基因改变与未达到12个月PSA nadir<0.2 ng/mL相关(HR 0.49 [95%CI 0.24, 0.98],p=0.047)。
关键数值与推荐
- ER定义为PFS>53.36个月(上四分位),NR定义为PFS<10.41个月(下四分位)。
临床怎么用
- 治疗前可结合临床特征(ECOG、疼痛、瘤负荷、血红蛋白、白蛋白、碱性磷酸酶)和基因组改变(TP53、MYC、BRCA2、RAD21等)评估ADT/ARPI治疗获益可能性。
局限性
- 回顾性设计,部分患者未接受分子检测,ER和NR定义基于PFS四分位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying clinical and genomic predictors of response to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) for metastatic androgen pathway modulator sensitive (APMS) prostate cancer is essential for improving therapeutic decision-making. Divergent outcomes are observed in practice, with some achieving exceptional responses (ER) while others experience early resistance or non-response (NR), the biologic basis of which remains unclear. METHODS: A retrospective review was conducted of patients with APMS prescribed ADT/ARPI from 2015-2024. ER and NR were defined by upper ( > 53.36 months) and lower ( < 10.41 months) quartiles of progression-free survival (PFS). Objectives were to associate baseline genomic and clinical factors with ER/NR status, PFS, overall survival (OS) and PSA kinetics.. RESULTS: Among 3363 prescribed ADT/ARPI, 224 were treated for APMS, with 154 (69%) undergoing temporal molecular testing. Alteration of ≥1 tumor suppressor gene with or without proliferative gene co-alteration was associated with NR while no single alteration predicted achieving ER. ECOG < 1, lack of pain, low-volume disease, higher hemoglobin and albumin, and normal alkaline phosphatase were associated with improved PFS, OS, and PSA nadir <0.2 ng/mL at 12 months. Alterations in TP53 (HR 1.60 [95%CI 1.02-2.50], p = 0.039; HR 1.91 [95%CI 1.05-3.49], p = 0.035) and MYC (HR 2.01 [95%CI 1.03-3.91], p = 0.040; HR 3.81 [95%CI 1.81-7.99], p < 0.001) were associated with inferior PFS and OS, while BRCA2 (HR 2.12 [95%CI 1.02-4.42], p = 0.045) additionally associated with PFS, and RAD21 (HR 2.55 [95%CI 1.13-5.77], p = 0.024) with OS. On multivariable analysis, MYC gain associated with OS (HR 4.41 [95%CI 1.24-15.7], p = 0.022). Pathway-level analysis showed proliferative gene alterations were associated with failure to achieve PSA nadir <0.2 ng/mL at 12 months (HR 0.49 [95%CI 0.24, 0.98], p = 0.047). CONCLUSIONS: In this real-world APMS cohort, we identified pre-treatment clinical and genomic predictors of patient benefits and long-term survival with ADT/ARPI therapy.
引用
- McKenzie J, Howard L, Park JJ, et al. Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer. Prostate Cancer Prostatic Dis. 2026. PMID: 42557372. doi:10.1038/s41391-026-01145-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。